1. Homepage
  2. Equities
  3. Italy
  4. Borsa Italiana
  5. Recordati
  6. News
  7. Summary
    REC   IT0003828271

RECORDATI

(REC)
  Report
Real-time Estimate Cboe Europe  -  05/16 11:12:07 am EDT
41.79 EUR   +1.08%
05/10Recordati Industria Chimica e Farmaceutica S.p.A. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/10Recordati Industria Chimica Seeks M&A
CI
05/10TRANSCRIPT : Recordati Industria Chimica e Farmaceutica S.p.A., Q1 2022 Earnings Call, May 10, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

RECORDATI: KIM STRATTON CO-OPTED TO THE BOARD OF DIRECTORS AS A NON-EXECUTIVE AND NON-INDEPENDENT DIRECTOR

12/16/2021 | 08:39am EDT

NEWS RELEASE

RECORDATI: KIM STRATTON CO-OPTED TO THE BOARD OF DIRECTORS AS A NON-EXECUTIVE AND NON-INDEPENDENT DIRECTOR

  • Disclosure in compliance with Recommendation No. 31 of the Corporate Governance Code
  • Payment dates for the 2021 dividend balance and the 2022 interim dividend announced.

Milan, 16 December 2021 - At its meeting today, the Recordati Board of Directors co-opted Kim Stratton as a non-executive and non-independent director, replacing Francesco Balestrieri, who resigned with effect from 15 October to take up a new professional appointment.

Kim Stratton has 30+ years experience in Biopharmaceuticals as CEO, C-Suite and Non-Exec Director, and has held a variety of senior commercial leadership roles at both Global and country level, combined with experience in Global External & Public Affairs, HSE and Compliance & Diversity across developed and emerging markets.

She is recognised for her strong track record leading turnaround & business transformations and integrations in the rare diseases, specialty and primary care businesses.

She is currently a Non-Executive Director and member of Nomination and Remuneration Committee and Innovation committees for Novozymes A/S, a leading Biotech in industrial enzymes, proteins and microorganisms and a Non-Executive Director and member of the Audit and Innovation committees for Vifor, a Global Specialty Pharma leader in nephrology, cardio-renal and iron deficiency therapies.

In compliance with Art. 2386 of the Italian Civil Code and applicable bylaws, the new director will remain in office until the next Shareholders' Meeting.

Based on the disclosures made by the Company, Kim Stratton holds no Company shares as of today's date.

"On behalf of the Board of Directors, I am pleased to welcome Kim Stratton. With her deep experience in the biopharmaceutical sector I am confident that she will make an excellent contribution to the Group and the Board ", stated Chairman Andrea Recordati.

***************************************

Disclosure pursuant to Recommendation No. 31 of the Corporate Governance Code and Art. 2.6.2 of the Rules of the Markets organised and managed by Borsa Italiana S.p.A.

Severance for Andrea Recordati on termination of mandate

Following on from the announcements made on 16 July 2021 and 1 December 2021 with regard to the agreement to finalise the termination of Andrea Recordati as Chief Executive Officer with effect from 1 December 2021, the Company announces that, in line with the 2021 Remuneration Policy, Andrea Recordati shall be paid EUR 350,768.46 with his December payslip as severance pay for the end of his mandate.

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Registered office

Via Matteo Civitali, 1

Fully paid-up share capital €26,140,644.50

20148 Milan, Italy

Business Register of Milan, Monza, Brianza and Lodi 00748210150

Tel. (+39) 02 487871

Tax Code/Vat No. 00748210150

Fax (+39) 02 40073747

Milan Economic and Administrative Index 401832

www.recordati.it

Company subject to management and coordination by Rossini Luxembourg S.àr.l

Payment dates for the 2021 dividend balance and the 2022 interim dividend

In line with and following on from the press release published on 11 October 2021 referring to the 2022 corporate events calendar, Recordati S.p.A. announces that the payment of the balance of the 2021 financial year dividend is planned for 25 May 2022 on each outstanding share at 23 May 2022 (ex-dividend date) and record date at 24 May 2022, whereas the payment of the interim dividend for the 2022 financial year is planned for 23 November 2022 on each outstanding share at 21 November 2022 (ex-dividend date) and record date at 22 November 20221.

Recordati (Reuters RECI.MI, Bloomberg REC IM), established in 1926, is an international pharmaceutical group listed on the Italian Stock Exchange (ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in Europe, Russia and other countries of the CIS, Ukraine, Turkey, North Africa, the United States, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under licence, from a number of therapeutic areas, including a specialised business dedicated to rare diseases. Recordati is a partner of choice for new product licences for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2020 was €1,448.9 million, operating income was €469.0 million and net income was €355.0 million.

Further information:

Recordati website: www.recordati.it

Investor Relations

Investor Relations

Press Office

Federica De Medici

Lucia Abbatantuoni

Brunswick - Barbara Scalchi / Andrea Mormandi

(39) 02 48787146

(39) 02 48787213

(39) 02 9288 6200

Email: investorelations@recordati.it

Email: investorelations@recordati.it

Email: recordati@brunswickgroup.com

1 Recordati S.p.A. specifies that this press release has no value in terms of forecasting that the conditions for the dividend distribution will exist.

Disclaimer

Recordati S.p.A. published this content on 16 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 December 2021 13:38:08 UTC.


ę Publicnow 2021
All news about RECORDATI
05/10Recordati Industria Chimica e Farmaceutica S.p.A. Reports Earnings Results for the Firs..
CI
05/10Recordati Industria Chimica Seeks M&A
CI
05/10TRANSCRIPT : Recordati Industria Chimica e Farmaceutica S.p.A., Q1 2022 Earnings Call, May..
CI
05/10Recordati Confirms 2022 Financial Targets
MT
05/10Recordati confirms 2022 targets despite Ukraine conflict
RE
05/10RECORDATI : 1st quarter results
CO
05/10RECORDATI : 1st quarter report
CO
04/29RECORDATI : THE SHAREHOLDERS' MEETING APPROVES THE 2021 FINANCIAL STATEMENTS. DIVIDEND OF ..
PU
04/29RECORDATI : Proxy Statments
CO
04/08RECORDATI – APPOINTMENT OF THE : Publication of the slate and of the resolution prop..
PU
More news
Analyst Recommendations on RECORDATI
More recommendations
Financials
Sales 2022 1 758 M 1 830 M 1 830 M
Net income 2022 391 M 407 M 407 M
Net Debt 2022 1 398 M 1 455 M 1 455 M
P/E ratio 2022 22,8x
Yield 2022 2,75%
Capitalization 8 499 M 8 847 M 8 847 M
EV / Sales 2022 5,63x
EV / Sales 2023 5,08x
Nbr of Employees 4 303
Free-Float 46,6%
Chart RECORDATI
Duration : Period :
Recordati Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RECORDATI
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Last Close Price 41,34 €
Average target price 47,24 €
Spread / Average Target 14,3%
EPS Revisions
Managers and Directors
Robert Koremans Chief Executive Officer
Luigi Felice la Corte Group Chief Financial Officer
Andrea Recordati Chairman
Raffaele Sabia Senior VP-Pharmaceutical Research & Development
Giovanni Minora Head-Group Audit & Compliance
Sector and Competitors
1st jan.Capi. (M$)
RECORDATI-26.83%8 847
JOHNSON & JOHNSON3.38%465 363
PFIZER, INC.-15.46%280 096
ABBVIE INC.13.37%271 251
ELI LILLY AND COMPANY5.58%262 514
ROCHE HOLDING AG-15.85%258 421